Navigation Links
Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
Date:9/18/2007

perating Officer. "These phase II data reinforce our belief that aclidinium has the potential to be a significant addition to the existing armamentarium of COPD treatments."

Methodology

The phase IIa study of aclidinium was a two-center, double-blind, randomized, ascending single-dose, placebo-controlled, cross-over trial which enrolled 17 patients with moderate to severe COPD. Treatment was with one of three doses of aclidinium (100 micrograms, 300 micrograms or 900 micrograms) or placebo-administered via dry-powder inhaler. The study's primary outcome measure was area under the normalized curve (AUC) of FEV1 over a 24-hour time period.

Findings of a phase I single-dose study, also presented at ERS 2007, demonstrate the bronchodilatory effects of aclidinium.(2) In the phase I study, in 12 healthy volunteers, bronchoconstriction was induced with methacholine challenge and then treated with one of three doses of aclidinium. Aclidinium proved superior to placebo in improving specific airway conductance. Aclidinium also provided statistically significant and sustained protection against methacholine-induced airway constriction over 24 hours. Aclidinium was well-tolerated throughout the trial. Headache was reported by two subjects and one subject experienced a serious adverse event which was not considered to be related to study drug.

Results of preclinical studies also presented at the congress show aclidinium's selectivity, long duration of action and rapid clearance from the plasma.(3,4) When compared to other bronchodilatory agents in vitro, aclidinium demonstrated potent anticholinergic activity comparable to both tiotropium and ipratropium, but with a faster onset of action than tiotropium and a significantly longer duration of action versus ipratropium, allowing for 24- hour duration of action.(4)

Notes:

FEV1 - Forced expiratory volume at 1 second

FVC - Forced vital capacity

ECG - Electrocardiogram

About COPD<
'/>"/>

SOURCE Forest Laboratories
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , July 30, 2015 ... latest report titled, "Continuous Glucose Monitoring Systems Market: Global ... to the report, the global continuous glucose monitoring systems ... and is expected to reach US$ 788.4 Mn by ... period, 2015 to 2020. Global continuous glucose ...
(Date:7/30/2015)... July 30, 2015 ... report with market overview, trends, DRO analysis, ... analysis, recent developments, competitive scenario and top ... Insight: Biosensors Market Development and Demand Forecast ... http://photos.prnewswire.com/prnh/20150727/756778 ) Explore more about ...
(Date:7/30/2015)... July 30, 2015  Medimetriks Pharmaceuticals, Inc. announced ... Phase III clinical study for Ozenoxacin, a novel ... owns the exclusive U.S. rights to Ozenoxacin 1% ... at 44 centers with an emphasis on U.S. ... 2 months and older with a clinical diagnosis ...
Breaking Medicine Technology:Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 2Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 3Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 4Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 2Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 3Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 4Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 5Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 2Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 3
(Date:7/30/2015)... ... 30, 2015 , ... The Beryl Institute announces its sixth ... with Patient Experience Institute, these offerings reinforce the commitment to help frame and ... throughout the experience movement, and provide information and research to support expanded focus ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... as the company and UCLA’s Jonsson Comprehensive Cancer Center (JCCC) mutually ... With the new collaboration, OncLive’s editorial and marketing groups will help spread the ...
(Date:7/30/2015)... ... ... Ross A. Clevens, MD, FACS has been reappointed by the University ... This is Dr. Clevens’ second appointment by the prestigious school. Over the past ... and a valuable mentoring program for medical students. , The University ...
(Date:7/30/2015)... ... July 30, 2015 , ... Zejax ... New Tool That Increases Training Capability , World renown body weight trainer, ... ( http://www.Zejax.com ), that dramatically increases a person’s training capability. , The American ...
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... ... of the ‘Mary Jo Lawyer-Spano Mesothelioma Patient Registry Act of 2015’. The ... (D-IL), Chris Collins (R-NY), Peter King (R-NY), Betty McCollum (D-MN), Joe Kennedy (D-MA), ...
Breaking Medicine News(10 mins):Health News:The Beryl Institute Opens Applications for 2015 Patient Experience Grant and Scholar Programs 2Health News:The Beryl Institute Opens Applications for 2015 Patient Experience Grant and Scholar Programs 3Health News:UCLA Jonsson Comprehensive Cancer Center Teams with OncLive® as a Strategic Alliance Partner 2Health News:UCLA Jonsson Comprehensive Cancer Center Teams with OncLive® as a Strategic Alliance Partner 3Health News:UCLA Jonsson Comprehensive Cancer Center Teams with OncLive® as a Strategic Alliance Partner 4Health News:Leading Melbourne Facial Plastic Surgeon Reappointed by UCF 2Health News:Leading Melbourne Facial Plastic Surgeon Reappointed by UCF 3Health News:Zejax is a Revolutionary New Way of BodyWeight Training Without Weights 2Health News:Bill to Create Patient Registry for Deadly Cancer Introduced in Congress 2
... Innovative technology such as electronic wristbands is developed to ... Human errors. Wristbands are developed which provides information about ... used in hospitals now to prescribe, dispense and administer ... bands contain electronic system which is similar to the ...
... the clinical trials involving lung cancer patients and it ... a frontline therapy for those with lung cancer. One ... regime in the elderly patients is the tolerability and ... tyrosine kinase inhibitor erlotinib (Tarceva) has demonstrated encouraging activity ...
... of Fair Trading is responsible for checking the profits ... to the NHS. They have to monitor that only ... should be reasonable. ,The Pharmaceutical Price Regulation ... legislates the agreement of the pricing and quality of ...
... out of deprivation from being in poverty and poor ... for heart disease is potentially denying// life saving preventive ... published ahead of print in the journal Heart. ... being allocated "primary preventive" treatment, is currently calculated using ...
... Mammography is used for early detection of breast cancer and ... year and self examination of the breasts for lumps every ... of cancer is necessary to start an early treatment which ... reported in the New England Journal of Medicine has shown ...
... called villi which increase the surface area of the intestine ... are covered in epithelial cells // which are constantly renewed ... top of the villi every day. ,Scientists found ... the bowel which, in healthy tissue, are immediately filled with ...
Cached Medicine News:Health News:Tarceva Found To Benefit Older Lung Cancer Patients 2Health News:Pharmaceutical industries grant for R&D to be monitored 2Health News:Deprivation Can Cause Undetected Heart Problems 2Health News:Digital Mammogram For Detection Of Breast Cancer In Women With Dense Breasts 2